Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Raloxifene, a selective estrogen receptor modulator approved for the prevention and treatment of postmenopausal osteoporosis, has shown a significant reduction in breast cancer incidence after 3 years in this placebo-controlled, randomized clinical trial in postmenopausal women with osteoporosis. This article includes results from an additional annual mammogram at 4 years and represents 3,004 additional patient-years of follow-up in this trial. Breast cancers were ascertained through annual screening mammograms and adjudicated by an independent oncology review board. A total of 7,705 women were enrolled in the 4-year trial; 2,576 received placebo, 2,557 raloxifene 60 mg/day, and 2,572 raloxifene 120 mg/day. Women were a mean of 66.5-years old at trial entry, 19 years postmenopause, and osteoporotic (low bone mineral density and/or prevalent vertebral fractures). As of 1 November 1999, 61 invasive breast cancers had been reported and were confirmed by the adjudication board, resulting in a 72% risk reduction with raloxifene (relative risk (RR) 0.28, 95% confidence interval (CI) 0.17, 0.46). These data indicate that 93 osteoporotic women would need to be treated with raloxifene for 4 years to prevent one case of invasive breast cancer. Raloxifene reduced the risk of estrogen receptor-positive invasive breast cancer by 84% (RR 0.16, 95% CI 0.09, 0.30). Raloxifene was generally safe and well-tolerated, however, thromboembolic disease occurred more frequently with raloxifene compared with placebo (p=0.003). We conclude that raloxifene continues to reduce the risk of breast cancer in women with osteoporosis after 4 years of treatment, through prevention of new cancers or suppression of subclinical tumors, or both. Additional randomized clinical trials continue to evaluate this effect in postmenopausal women with osteoporosis, at risk for cardiovascular disease, and at high risk for breast cancer.
Cauley
J A
JA
Department of Epidemiology, University of Pittsburgh, PA 15261, USA.
Norton
L
L
Lippman
M E
ME
Eckert
S
S
Krueger
K A
KA
Purdie
D W
DW
Farrerons
J
J
Karasik
A
A
Mellstrom
D
D
Ng
K W
KW
Stepan
J J
JJ
Powles
T J
TJ
Morrow
M
M
Costa
A
A
Silfen
S L
SL
Walls
E L
EL
Schmitt
H
H
Muchmore
D B
DB
Jordan
V C
VC
Ste-Marie
L G
LG
D000368:Aged; D000369:Aged, 80 and over; D001315:Australia / Q000453:epidemiology; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000517:prevention & control*; D004311:Double-Blind Method; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005060:Europe / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008327:Mammography; D008875:Middle Aged; D009520:New Zealand / Q000453:epidemiology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D017698:Postmenopause; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D016217:Ultrasonography, Mammary; D014481:United States / Q000453:epidemiology
D004965:Estrogen Antagonists; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride